Clinical Trial Update: Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease [Phase 4]

View source ↗

Summary

A Phase 4 study comparing safety and efficacy of Cerezyme infusions every 4 weeks versus every 2 weeks in Type 1 Gaucher disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• CEREZYME (imiglucerase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2009-09-02